- Home
- ORC vs DNTH Comparison
ORC vs DNTH Comparison
Compare ORC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- DNTH
- Stock Information
- Founded
- ORC 2010
- DNTH 2015
- Country
- ORC United States
- DNTH United States
- Employees
- ORC N/A
- DNTH N/A
- Industry
- ORC Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ORC Real Estate
- DNTH Health Care
- Exchange
- ORC Nasdaq
- DNTH Nasdaq
- Market Cap
- ORC 660.1M
- DNTH 606.2M
- IPO Year
- ORC 2013
- DNTH N/A
- Fundamental
- Price
- ORC $7.17
- DNTH $21.50
- Analyst Decision
- ORC Hold
- DNTH Strong Buy
- Analyst Count
- ORC 3
- DNTH 8
- Target Price
- ORC N/A
- DNTH $53.00
- AVG Volume (30 Days)
- ORC 4.4M
- DNTH 371.6K
- Earning Date
- ORC 07-24-2025
- DNTH 08-11-2025
- Dividend Yield
- ORC 20.08%
- DNTH N/A
- EPS Growth
- ORC N/A
- DNTH N/A
- EPS
- ORC 0.07
- DNTH N/A
- Revenue
- ORC $24,257,000.00
- DNTH $6,524,000.00
- Revenue This Year
- ORC $70.18
- DNTH N/A
- Revenue Next Year
- ORC $49.05
- DNTH N/A
- P/E Ratio
- ORC $101.16
- DNTH N/A
- Revenue Growth
- ORC N/A
- DNTH 102.36
- 52 Week Low
- ORC $5.69
- DNTH $13.37
- 52 Week High
- ORC $9.01
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- ORC 43.97
- DNTH 58.34
- Support Level
- ORC $7.03
- DNTH $20.00
- Resistance Level
- ORC $7.48
- DNTH $23.21
- Average True Range (ATR)
- ORC 0.14
- DNTH 1.28
- MACD
- ORC -0.02
- DNTH -0.05
- Stochastic Oscillator
- ORC 13.89
- DNTH 58.09
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.